#1 Clinical Trials Search in Europe

Cart45Ra-Nkg2D Cells

CART45RA-NKG2D Cells are being studied in clinical trials as a potential treatment for refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults, as well as for advanced sarcoma. This innovative cell therapy uses genetically modified T cells to target cancer cells more effectively. The trials aim to evaluate the safety, feasibility, and efficacy of this promising approach in patients who have not responded to conventional treatments.

Table of Contents

What is CART45RA-NKG2D?

CART45RA-NKG2D is an innovative cell therapy being studied for the treatment of certain types of cancer[1]. It belongs to a class of treatments called CAR-T cell therapy, which stands for Chimeric Antigen Receptor T-cell therapy. This treatment involves modifying a patient’s own immune cells (T cells) or donor cells to better recognize and fight cancer cells.

Target Conditions

CART45RA-NKG2D is being investigated for two main types of cancer:

  • Refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults[1]
  • Advanced sarcoma in children, adolescents, and young adults[3]

These conditions are typically difficult to treat with standard therapies, especially when they have come back (relapsed) or are not responding to treatment (refractory).

How It Works

CART45RA-NKG2D cells are designed to target specific proteins on cancer cells. For ALL, they target proteins called CD19 and CD22 on B-cell leukemia cells, or NKG2D ligands on T-cell leukemia cells[1]. For sarcoma, they target NKG2D ligands on tumor cells[3]. These modified T cells are equipped with a special receptor (CAR) that helps them recognize and attack cancer cells more effectively.

Clinical Trials

CART45RA-NKG2D is currently being studied in Phase I clinical trials. These trials aim to:

  • Determine the safety and feasibility of the treatment
  • Find the right dose that can be tolerated by patients
  • See how well the treatment works against the cancer
  • Understand how long the modified T cells stay in the body
  • Study the effects on the immune system and cancer cells[1][2][3]

Eligibility Criteria

To participate in these trials, patients generally need to meet certain criteria, including:

  • Age: Usually under 30 or 40 years old at diagnosis or relapse
  • Having cancer that has not responded to or has come back after standard treatments
  • Good overall health status
  • Adequate organ function
  • For sarcoma trials, having tumors that express certain proteins (NKG2D ligands)[1][3]

Administration

CART45RA-NKG2D cells are given as an intravenous infusion, which means they are delivered directly into the bloodstream. The treatment may be given in multiple doses, depending on the specific trial and the patient’s response[1][3].

Potential Benefits

While it’s important to remember that CART45RA-NKG2D is still in early stages of research, potential benefits being studied include:

  • Ability to target cancer cells that have become resistant to other treatments
  • Potential for long-lasting effects as the modified T cells can persist in the body
  • Possibility of achieving remission in patients who have run out of other treatment options[1][2][3]

Safety Considerations

As with any experimental treatment, there are potential risks and side effects. The clinical trials are carefully monitoring for:

  • Cytokine release syndrome (CRS): A condition where the immune system becomes overly activated
  • Infections
  • Effects on normal blood cells
  • Any unexpected side effects[1][2][3]

Patients in the trials are closely monitored and receive supportive care as needed to manage any side effects.

Aspect Details
Treatment CART45RA-NKG2D Cells
Cancer Types Refractory/relapsed acute lymphoblastic leukemia (ALL), Advanced sarcoma
Patient Age Children, adolescents, and young adults (up to 30 or 40 years old)
Administration Intravenous infusion, potentially combined with local administration
Trial Phase Phase I
Primary Objectives Safety, feasibility, dose-limiting toxicity, maximum tolerated dose
Secondary Objectives Efficacy, cell persistence, cytokine profiles, biomarker analysis
Key Eligibility Refractory/relapsed disease, no standard treatment options available

FAQ

  • What is CART45RA-NKG2D Cell therapy? CART45RA-NKG2D Cell therapy is a type of immunotherapy that uses genetically modified T cells to target and fight cancer cells. These cells are engineered to express a chimeric antigen receptor (CAR) that recognizes specific proteins on cancer cells, potentially improving the immune system's ability to attack the cancer.
  • What types of cancer are being studied with CART45RA-NKG2D Cells? The clinical trials are focusing on refractory/relapsed acute lymphoblastic leukemia (ALL) in children, adolescents, and young adults, as well as advanced sarcoma in patients up to 40 years old.
  • How is the therapy administered? The therapy is administered through intravenous infusion. In some trials, patients receive multiple infusions over several days, while in others, the therapy may be given both systemically (through the bloodstream) and locally (directly into the tumor).
  • What are the main goals of these clinical trials? The main goals of these trials are to determine the safety, feasibility, and potential efficacy of CART45RA-NKG2D Cell therapy. Researchers are also studying the persistence of the modified T cells in the body, their effects on the tumor, and any potential side effects.
  • Who is eligible for these clinical trials? Eligibility varies by trial, but generally includes patients under 30 or 40 years old with refractory/relapsed ALL or advanced sarcoma that has not responded to standard treatments. Specific health criteria and the presence of certain proteins on the cancer cells may also be required for participation.

Ongoing Clinical Trials on Cart45Ra-Nkg2D Cells

  • Study on CART 19/22 T Cells and CART45RA-NKG2D Cells for Treating Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on CART45RA-NKG2D Cells for Children, Adolescents, and Young Adults with Advanced Sarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Feasibility of CART 19/22 T Cells and CART45RA-NKG2D Cells for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of cancer that affects the blood and bone marrow, causing the body to produce too many immature white blood cells.
  • Sarcoma: A type of cancer that develops in bones and soft tissues such as muscles, tendons, and blood vessels.
  • CAR-T Cell Therapy: A type of treatment that uses genetically modified T cells (a type of immune cell) to better recognize and attack cancer cells.
  • Refractory: Refers to a disease that does not respond to treatment.
  • Relapsed: Refers to the return of a disease after a period of improvement.
  • Chimeric Antigen Receptor (CAR): A protein engineered to be added to T cells, allowing them to recognize specific proteins on cancer cells.
  • NKG2D: A receptor found on certain immune cells that can recognize stress-induced molecules on cancer cells.
  • Dose-limiting toxicity (DLT): Side effects of a treatment that are severe enough to prevent an increase in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a treatment that does not cause unacceptable side effects.
  • Cytokines: Small proteins released by cells that have specific effects on cell interactions and communication.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-feasibility-of-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-children-adolescents-and-young-adults-with-acute-lymphoblastic-leukemia/
  2. http://clinicaltrials.eu/trial/study-on-cart-19-22-t-cells-and-cart45ra-nkg2d-cells-for-treating-refractory-relapsed-acute-lymphoblastic-leukemia-in-children-adolescents-and-young-adults/
  3. http://clinicaltrials.eu/trial/study-on-cart45ra-nkg2d-cells-for-children-adolescents-and-young-adults-with-advanced-sarcoma/